Comparative efficacy and safety of colistin-based and alternative antibiotic regimens for multidrug-resistant Gram-negative infections: A systematic review and network meta-analysis.
Ajaree Rayanakorn, Thitiya Lukkunaprasit, Shaun Lee Wen Huey et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and network meta-analysis evaluated the efficacy and safety of colistin-based regimens versus alternative antibiotics for multidrug-resistant Gram-negative infections in 1760 patients. The study found that beta-lactam therapy with a beta-lactamase inhibitor significantly reduced all-cause mortality compared to colistin monotherapy (RR 0.62).
Key findings
- Beta-lactam therapy with a beta-lactamase inhibitor reduced all-cause mortality compared to colistin monotherapy (RR 0.62).
- Colistin-based combination therapies showed higher clinical cure rates than colistin monotherapy (RR 4.43).
- Microbiological eradication rates were significantly higher with colistin-based combinations (RR 9.50).
- Beta-lactam/beta-lactamase inhibitor regimens had lower nephrotoxicity risks compared to colistin-based regimens.
Why it matters
Understanding the comparative effectiveness of antibiotic regimens for multidrug-resistant infections is crucial for optimizing treatment strategies and improving patient outcomes, particularly in the context of rising antibiotic resistance.
What to keep in mind
The evidence quality was low to very low, limiting the ability to draw firm conclusions about treatment effects.